- From www.fun-mooc.fr
Vaccinology
You can't access an archived course
- Free Access
- Free certificate
- 32 Sequences
- Introductive Level
- Starts on December 4, 2016
- Ends on September 3, 2019
Course details
Syllabus
- History of vaccines including IP
- Smallpox eradication
- Polio eradication
- Modeling in vaccinology
- Antigen discovery
- Immune memory of vaccines
- Vaccines for pregnant women
- Vaccines for neonates
- Correlates of protection
- Adjuvants
- Delivery of vaccines
- On the importance of maintaining vaccine coverage
- Epidemiology post vaccination: pertussis vaccine example
- GMP production
- Immuno-monitoring
- Phase I/II clinical trials
- Phase III clinical trials
- Success of glycoconjugate vaccines
- Rotavirus vaccines
- HPV vaccines
- Influenza vaccines
- TB vaccines
- RSV vaccines
- HIV vaccines
- Malaria vaccines
- Vaccines against neglected parasites and worms
- Innovation in future vaccines
- Vaccines for the elderly
- Vaccine economics
- Globalization of vaccine production
- Vaccine implementation on the field
- Vaccine perception
Prerequisite
Background in microbiology, immunology, public health
Connaissances en microbiology, immunology, santé publique.
Instructors
Armelle Phalipon
Armelle Phalipon is a microbiologist leading a group within the Molecular Microbial Pathogenesis Unit, INSERM U786, at the Institut Pasteur, Paris, France. Working in the field of diarrheal diseases, her team is interested in deciphering the cross-talks between enteropathogenic bacteria and the host immune system. The main current studies aim at deciphering how Shigella, the bacterium responsible for bacillary dysentery, impacts on the development of the short-term, poorly effective protective immunity elicited in response to infection. Armelle Phalipon has a long-standing interest in combining fundamental and applied research. Indeed, in collaboration with Dr. Laurence Mulard (Institut Pasteur, Paris), she has designed a new type of Shigella vaccine candidate that will enter a phase 1 clinical trial in 2016 for proof of concept in humans. She is co-founder and co-director with Frédéric Tangy of the first International Vaccinology Course launched at the Pasteur Institute in 2008.
Frédéric Tangy
Frédéric Tangy, PhD, Dr.Sc., Director of Research at CNRS, is the head of the Viral Genomics and Vaccination Research Unit at Institut Pasteur, Paris (CNRS UMR-3569). After his PhD in 1980 and his Dr. Sc. in 1984 at Paris VI University he made his career as a virologist first at CNRS then at Institut Pasteur. He is co-director of the international Vaccinology course of Institut Pasteur, vice-president of the Scientific Council of Institut Pasteur, and member of ASM, ESGT, IAS, SFI. He is the author of 110 publications in international scientific journals and 19 international patents. In the recent years, he has developed two research programs: 1) generation of polyvalent viral attenuated vaccines based on a vector derived from measles vaccine. This project extends from the design of antigens and generation of recombinant vectors, to preclinical and clinical development in the field of HIV, dengue, chikungunya and malaria vaccines. 2) The second project investigates the interactions between viral and host proteins in a systematic way using functional genomic approaches such as high-throughput cloning, yeast two-hybrid, deep sequencing and high-throughput drug screening. This project aims at understanding at a molecular level the interactions between viral and host proteins and RNA in the field of paramyxoviruses. These observations lead to identify new drug targets and new determinants of pathogenicity/attenuation.
Editor
The Institut Pasteur is a private, not-for-profit French foundation based in Paris, dedicated to the study of biology, micro-organisms, diseases and vaccines.
Created in 1888 thanks to an international public subscription, it is named after Louis Pasteur1, its founder and first director, who in 1885 developed the first vaccine against rabies.
For over a century, the Institut Pasteur has been at the forefront of the fight against infectious diseases. In 1983, this international research organisation was the first to isolate the human immunodeficiency virus (HIV), the virus that causes acquired immunodeficiency syndrome (AIDS). Over the years, it has been responsible for revolutionary discoveries that have enabled medicine to control virulent diseases such as diphtheria, tetanus, tuberculosis, poliomyelitis, influenza, yellow fever, epidemic plague, hepatitis B and AIDS.
Platform
France Université Numérique is the broadcaster of the online courses of French higher education institutions and their partners.
It operates several platforms of diffusion, of which the best known, FUN MOOC, is the first French-speaking academic platform worldwide. Thanks to many partner institutions, this platform offers a vast catalog of courses enriched daily with various themes and current events.